Impact of prior CAR-T cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
Chong EA, Penuel E, Napier EB, Lundberg RK, Budde LE, Shadman M, Matasar MJ, Bartlett NL, Flinn IW, Bosch F, Fay K, Goy A, Kumar A, Nastoupil LJ, Wei MC, Wu M, Yin S, Fraietta JA, Chong ER, Schuster SJ.
Chong EA, et al. Among authors: wu m.
Blood Adv. 2024 Nov 21:bloodadvances.2024013640. doi: 10.1182/bloodadvances.2024013640. Online ahead of print.
Blood Adv. 2024.
PMID: 39571171